Structure Therapeutics (GPCR) Total Non-Current Liabilities (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Total Non-Current Liabilities of $60.2 million for Q1 2026, up 44.62% year-over-year from $41.6 million in Q1 2025, and down 10.06% quarter-over-quarter from $66.9 million in Q4 2025.
Structure Therapeutics (GPCR) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Structure Therapeutics' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $60.2 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 44.62% year-over-year to $60.2 million; the TTM figure through Mar 2026 stood at $60.2 million (up 44.62% YoY), while the FY2025 annual figure was $66.9 million, up 75.18% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $60.2 million, down from $66.9 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $66.9 million in Q4 2025, with the low at $13.0 million in Q4 2022.
- The 5-year median for Total Non-Current Liabilities is $37.1 million (2024), against an average of $38.9 million.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities jumped 121.01% in 2023, then surged 32.8% in 2024.
- Structure Therapeutics' Total Non-Current Liabilities stood at $13.0 million in 2022, then surged by 121.01% to $28.8 million in 2023, then jumped by 32.8% to $38.2 million in 2024, then soared by 75.18% to $66.9 million in 2025, then retreated by 10.06% to $60.2 million in 2026.
- Business Quant data shows GPCR's Total Non-Current Liabilities at $60.2 million in Q1 2026, $66.9 million in Q4 2025, and $61.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | 69.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 69.75 Mn |
| Mar 31, 2026 | 60.17 Mn |
| Dec 31, 2025 | 66.89 Mn |
| Sep 30, 2025 | 61.82 Mn |
| Jun 30, 2025 | 44.05 Mn |
| Mar 31, 2025 | 41.60 Mn |
| Dec 31, 2024 | 38.19 Mn |
| Sep 30, 2024 | 36.11 Mn |
| Jun 30, 2024 | 26.00 Mn |
| Mar 31, 2024 | 27.11 Mn |
| Dec 31, 2023 | 28.75 Mn |
| Sep 30, 2023 | 23.13 Mn |
| Dec 31, 2022 | 13.01 Mn |